Seagen Inc. which can be found using ticker (SGEN) now have 14 analysts in total covering the stock. The consensus rating is pointing to ‘hold’. The range between the high target price and low target price is between 229 and 180 calculating the average target price we see $222.64. Given that the stocks previous close was at $192.46 this would indicate that there is a potential upside of 15.7%. There is a 50 day moving average of $196.96 and the 200 day MA is $161.27. The company has a market capitalization of 36.47B. The current share price for the company is: 194.43 USD
The potential market cap would be $42,186,014,400 based on the market consensus.
The company has a dividend yield of 5.95%. Other points of data to note are a P/E ratio of -, revenue per share of 11.08 and a -11.6% return on assets.
Seagen Inc. is a biotechnology company that develops and commercializes targeted therapies to treat cancer. The Company is engaged in commercializing ADCETRIS, or brentuximab vedotin, for the treatment of certain CD30-expressing lymphomas; PADCEV, or enfortumab vedotin-ejfv, for the treatment of certain metastatic urothelial cancers; TUKYSA, or tucatinib, for the treatment of certain metastatic human epidermal growth factor receptor 2 (HER2) -positive breast and colorectal cancers, and TIVDAK, or tisotumab vedotin-tftv, for the treatment of certain metastatic cervical cancers. It is also advancing a pipeline of novel therapies for solid tumors and blood-related cancers designed to address unmet medical needs and improve treatment outcomes for patients. Its programs including ADCETRIS, PADCEV and TIVDAK, are based on the Company’s antibody-drug conjugate (ADC) technology that utilizes the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells.
